Sanofi (SNY - Free Report) announced that it is ending the development of the cancer program called tusamitamab ravtansine based on the outcome of a prespecified interim analysis conducted by an Independent Data Monitoring Committee (IDMC).
The CARMEN-LC03 study investigated tusamitamab ravtansine, a type of an antibody-drug conjugate, as a monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5.
The CARMEN-LC03 study had dual primary endpoints – progression-free survival (PFS) and overall survival (OS).
Shares of Sanofi have inched up 0.9% in the past year compared with the industry’s increase of 4.2%.
Per the finding of IDMC, tusamitamab ravtansine failed to meet the dual primary endpoint of improving PFS versus docetaxel in the CARMEN-LC03 study.
Although treatment with tusamitamab ravtansine demonstrated an improved OS trend, Sanofi decided to stop further clinical development of tusamitamab ravtansine based on non-improvement in PFS in the final analysis.
Despite the study data falling short of expectations, management will continue to explore the potential of tusamitamab-based antibody drug conjugates in several other types of cancer indications.
Antibody drug conjugates are being considered a disruptive innovation in the pharmaceutical industry as these allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 41.2%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 0.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have lost 4.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Sanofi (SNY - Free Report) announced that it is ending the development of the cancer program called tusamitamab ravtansine based on the outcome of a prespecified interim analysis conducted by an Independent Data Monitoring Committee (IDMC).
The CARMEN-LC03 study investigated tusamitamab ravtansine, a type of an antibody-drug conjugate, as a monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5.
The CARMEN-LC03 study had dual primary endpoints – progression-free survival (PFS) and overall survival (OS).
Shares of Sanofi have inched up 0.9% in the past year compared with the industry’s increase of 4.2%.
Per the finding of IDMC, tusamitamab ravtansine failed to meet the dual primary endpoint of improving PFS versus docetaxel in the CARMEN-LC03 study.
Although treatment with tusamitamab ravtansine demonstrated an improved OS trend, Sanofi decided to stop further clinical development of tusamitamab ravtansine based on non-improvement in PFS in the final analysis.
Despite the study data falling short of expectations, management will continue to explore the potential of tusamitamab-based antibody drug conjugates in several other types of cancer indications.
Antibody drug conjugates are being considered a disruptive innovation in the pharmaceutical industry as these allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Taro Pharmaceutical Industries Ltd. (TARO - Free Report) , Entrada Therapeutics, Inc. (TRDA - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Taro Pharmaceutical’s 2024 earnings per share have improved from 96 cents to $1.10. In the past year, shares of TARO have surged 41.2%.
Earnings of Taro Pharmaceutical beat estimates in two of the last four quarters while missing the same on the remaining two occasions. TARO delivered a four-quarter earnings surprise of 10.06%, on average.
In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from $2.35 to $2.04. In the past year, shares of TRDA have decreased 0.7%.
Earnings of Entrada Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. TRDA delivered a four-quarter average earnings surprise of 70.68%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 56 cents to 64 cents. In the past year, shares of PBYI have lost 4.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
Zacks Naming Top 10 Stocks for 2024
Want to be tipped off early to our 10 top picks for the entirety of 2024?
History suggests their performance could be sensational.
From 2012 (when our Director of Research, Sheraz Mian assumed responsibility for the portfolio) through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2024. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Be First to New Top 10 Stocks >>
Get the latest research report on SNY - FREE
Get the latest research report on TARO - FREE
Get the latest research report on PBYI - FREE
Get the latest research report on TRDA - FREE